Posted by Michael Wonder on 11 Jun 2019
Duchesnay is seeking Health Canada's approval for ospemifene for the treatment of moderate to severe dyspareunia and vaginal dryness, symptoms of vulvar and vaginal atrophy, a component of genitourinary syndrome of menopause
10 June 2019 - Duchesnay has filed a new drug submission with Health Canada for a once-daily oral ospemifene tablet, a non-hormonal SERM (selective oestrogen receptor modulator) for the treatment of moderate to severe dyspareunia and vaginal dryness, symptoms of vulvar and vaginal atrophy due to menopause, a component of genitourinary syndrome of menopause.
Dyspareunia and vaginal dryness are among the most common bothersome symptoms of VVA due to menopause. Before menopause, oestrogen helps maintain the thickness, elasticity and lubrication of vaginal tissues. However, as women age, oestrogen levels decrease, leading to significant structural changes in these tissues, resulting in dryness, itching and burning that cause painful sexual intercourse.
